Abstract:BACKGROUND:Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of progression to acute myeloid leukemia (AML). Treatment options are limited and targeted therapies are not available for MDS. In the present study, we investigated the cytotoxicity and the molecular mechanism of Homoharringtonine (HHT) and Bortezomib towards high-risk MDS cell line SKM-1 in vitro and the role of miR-3151 was first evaluated in SKM-1 cells.METHODS:SKM-1 cells were treated with different concentrations of HHT or Bortezomib, and cell viability was analyzed with CCK-8 assay. The influence on cell proliferation, cell cycle distribution and the percentage of apoptosis cells were analyzed by flow cytometry. Calcusyn software was used to calculate combination index (CI) values. Western blot was used to analysis phosphorylation of Akt and nuclear NF-κB protein expression in SKM-1 cells. Mature miR-3151 level and p53 protein level were detected after HHT or Bortezomib treatment. The cell proliferation and p53 protein level were reassessed in SKM-1 cells infected with lentivirus to overexpress miR-3151.RESULTS:Simultaneous exposure to HHT and Bortezomib (10.4:1) resulted in a significant reduction of cell proliferation in SKM-1 cells (P < 0.05). Cell cycle arrest at G0/G1 and G2/M phase was observed (P < 0.05). HHT and Bortezomib synergistically induced cell apoptosis by regulating members of caspase 9, caspase 3 and Bcl-2 family (P < 0.01). The mechanisms of the synergy involved Akt and NF-κB signaling pathway inhibition, downregulation of mature miR-3151 and increment of downstream p53 protein level. Overexpression of miR-3151 promoted cell proliferation and inhibited p53 protein expression in SKM-1 (P < 0.01).CONCLUSIONS:HHT and Bortezomib synergistically inhibit SKM-1 cell proliferation and induce apoptosis in vitro. Inhibition of Akt and NF-κB pathway signaling contribute to molecular mechanism of HHT and Bortezomib. miR-3151 abundance is implicated in SKM-1 cell viability, cell proliferation and p53 protein expression.

Genome-Wide Profiling of the Toxic Effect of Bortezomib on Human Esophageal Carcinoma Epithelial Cells.

SUMOylation Plays a Role in Gemcitabine- and Bortezomib-Induced Cytotoxicity in Human Oropharyngeal Carcinoma KB Gemcitabine-Resistant Clone.

Bortezomib Therapeutic Effect is Associated with Expression of Fgfr3 in Multiple Myeloma Cells

[Apoptosis in Jurkat Cells Induced by Bortezomib Combined with Adriamycin].

Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.

Effect of Bortezomib on Global Gene Expression in PC12-Derived Nerve Cells

Bortezomib Induces Apoptosis and Autophagy in Osteosarcoma Cells Through Mitogen-Activated Protein Kinase Pathway in Vitro

Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.

Antitumor Activity and Drug Interactions of Proteasome Inhibitor Bortezomib in Human High-Risk Myelodysplastic Syndrome Cells.

Bortezomib Potentiates Antitumor Activity of Mitoxantrone Through Dampening Wnt/β-catenin Signal Pathway in Prostate Cancer Cells

Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis.

Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL–Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways

2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy

Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.

Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib

Proteasome inhibitor bortezomib targeted tumor–endothelial cell interaction in T-cell leukemia/lymphoma

Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines]

Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.

[Study on the Relationship of Beta-Catenin Level and Sensitivity to Bortezomib of Myeloma Cell Lines].

[Effect of Bortezomib on Sensitization of HL-60 Cells to TRAIL].